Molecular determinants of myeloma bone disease and use thereof

Details Molecular determinants of myeloma bone disease and use thereof Molecular determinants of myeloma bone disease and use thereof

2006-10-26

2010-10-12

Kemmerer, Elizabeth C. (Department: 1646)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S006120, C435S007100

Reexamination Certificate

active

07811750

ABSTRACT:
To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3/FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to reduce tumor burden in multiple myeloma and to block bone disease.

REFERENCES:
patent: 7459437 (2008-12-01), Shaughnessy
patent: WO 0052047 (2000-09-01), None
Chappuis et al. (Cancer Treat Res. 2002; 107: 29-59).
McLaughlin et al. (Tannock, I.F. and Hill, R.P., The Basic Science of Oncology, Chapter 2, (3rd Ed., 1998).

Affiliated with

Also associated with

Rating

Molecular determinants of myeloma bone disease and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Molecular determinants of myeloma bone disease and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecular determinants of myeloma bone disease and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4171836